KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Corbin, Amie S., O’Hare, Thomas, Gu, Zhimin, Kraft, Ira L., Eiring, Anna M., Khorashad, Jamshid S., Pomicter, Anthony D., Zhang, Tian Y., Eide, Christopher A., Manley, Paul W., Cortes, Jorge E., Druker, Brian J., Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894913/
https://ncbi.nlm.nih.gov/pubmed/23887971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados